PPARG and metabolic dysfunction-associated steatotic liver disease: Similarly, LDT409, a partial agonist of PPARα and PPARγ, promoted weight loss by reducing hepatic lipid accumulation and TG through upregulation of fatty acid oxidation genes fatty acid binding protein 1 (Fabp1), cluster of differentiation 36 (Cd36), cytochrome p450 family 4 subfamily A member 14 (CYP4A14), enhancing thermogenesis and fatty acid oxidation in brown adipose tissue uncoupling protein 1 (Ucp1), carnitine palmitoyltransferase 1 (CPT1), and inducing browning in Ucp1 in the HFD-induced MASLD mouse model [24].